Alterations in complex lipids in tumor tissue of patients with colorectal cancer.
Aged
Aged, 80 and over
Colorectal Neoplasms
/ chemistry
Diglycerides
/ analysis
Female
Gas Chromatography-Mass Spectrometry
Humans
Lipid Metabolism
Lipids
/ analysis
Lysophospholipids
/ analysis
Magnetic Resonance Spectroscopy
Male
Middle Aged
Phospholipids
/ chemistry
Sphingolipids
/ analysis
Triglycerides
/ chemistry
Colorectal cancer
Liquid chromatography–mass spectrometry
Phospholipids
Sphingolipids
Triacylglycerols
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
04 Aug 2021
04 Aug 2021
Historique:
received:
08
05
2021
accepted:
26
07
2021
entrez:
5
8
2021
pubmed:
6
8
2021
medline:
20
1
2022
Statut:
epublish
Résumé
Accumulating evidence indicates alterations in lipid metabolism and lipid composition in neoplastic tissue. Earlier nuclear magnetic resonance studies showed that the contents of major lipid groups, such as triacylglycerols, phospholipids and cholesterol, are changed in colon cancer tissue. In this study, a more detailed analysis of lipids in cancer and tumor adjacent tissues from colorectal cancer patients, using liquid chromatography-mass spectrometry, allowed for comparison of 199 different lipids between cancer tissue and tumor adjacent tissue using principal component analysis. Significant differences were found in 67 lipid compounds between the two types of tissue; many of these lipid compounds are bioactive lipids such as ceramides, lysophospholipids or sterols and can influence the development of cancer. Additionally, increased levels of phospholipids and sphingolipids were present, which are major components of the cell membrane, and increases in these lipids can lead to changes in cell membrane properties. This study showed that many complex lipids are significantly increased or decreased in colon cancer tissue, reflecting significant alterations in lipid metabolism. This knowledge can be used for the selection of potential molecular targets of novel anticancer strategies based on the modulation of lipid metabolism and the composition of the cell membrane in colorectal cancer cells.
Sections du résumé
BACKGROUND
BACKGROUND
Accumulating evidence indicates alterations in lipid metabolism and lipid composition in neoplastic tissue. Earlier nuclear magnetic resonance studies showed that the contents of major lipid groups, such as triacylglycerols, phospholipids and cholesterol, are changed in colon cancer tissue.
METHODS
METHODS
In this study, a more detailed analysis of lipids in cancer and tumor adjacent tissues from colorectal cancer patients, using liquid chromatography-mass spectrometry, allowed for comparison of 199 different lipids between cancer tissue and tumor adjacent tissue using principal component analysis.
RESULTS
RESULTS
Significant differences were found in 67 lipid compounds between the two types of tissue; many of these lipid compounds are bioactive lipids such as ceramides, lysophospholipids or sterols and can influence the development of cancer. Additionally, increased levels of phospholipids and sphingolipids were present, which are major components of the cell membrane, and increases in these lipids can lead to changes in cell membrane properties.
CONCLUSIONS
CONCLUSIONS
This study showed that many complex lipids are significantly increased or decreased in colon cancer tissue, reflecting significant alterations in lipid metabolism. This knowledge can be used for the selection of potential molecular targets of novel anticancer strategies based on the modulation of lipid metabolism and the composition of the cell membrane in colorectal cancer cells.
Identifiants
pubmed: 34348720
doi: 10.1186/s12944-021-01512-x
pii: 10.1186/s12944-021-01512-x
pmc: PMC8340484
doi:
Substances chimiques
Diglycerides
0
Lipids
0
Lysophospholipids
0
Phospholipids
0
Sphingolipids
0
Triglycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
85Subventions
Organisme : Narodowe Centrum Nauki
ID : 2016/22/E/NZ4/00665
Informations de copyright
© 2021. The Author(s).
Références
Cell Signal. 2021 Feb;78:109850
pubmed: 33253914
Rapid Commun Mass Spectrom. 2013 Jan 15;27(1):24-34
pubmed: 23239314
Prostate. 2015 Dec;75(16):1821-30
pubmed: 26332786
World J Gastroenterol. 2014 Jul 14;20(26):8646-52
pubmed: 25024621
Sci Rep. 2016 Jul 20;6:29935
pubmed: 27435310
Nat Commun. 2017 Oct 20;8(1):1077
pubmed: 29057876
Obes Rev. 2017 Feb;18(2):247-272
pubmed: 27899022
Nat Rev Mol Cell Biol. 2017 Feb;18(2):90-101
pubmed: 27924077
Stem Cells. 2015 Jan;33(1):35-44
pubmed: 25186497
Sci Rep. 2020 Feb 6;10(1):1954
pubmed: 32029824
Prog Lipid Res. 2012 Jul;51(3):199-207
pubmed: 22465125
Expert Opin Investig Drugs. 2018 May;27(5):475-489
pubmed: 29723075
Methods Mol Biol. 2017;1609:91-106
pubmed: 28660577
Anticancer Res. 2019 Jul;39(7):3815-3822
pubmed: 31262909
Cell Physiol Biochem. 2017;41(2):722-730
pubmed: 28214830
World J Gastroenterol. 2014 Mar 7;20(9):2279-303
pubmed: 24605027
Curr Med Chem. 2019;26(1):60-103
pubmed: 28971757
Molecules. 2020 Nov 13;25(22):
pubmed: 33203044
J Lipid Res. 2020 Jun;61(6):840-858
pubmed: 32265321
Lipids Health Dis. 2019 Jan 26;18(1):29
pubmed: 30684960
EMBO Mol Med. 2019 Nov 7;11(11):e10698
pubmed: 31602788
Biomolecules. 2020 Apr 19;10(4):
pubmed: 32325909
Mass Spectrom Rev. 2018 Mar;37(2):107-138
pubmed: 27276657
Tumour Biol. 2019 May;41(5):1010428319848616
pubmed: 31106679
Cell Death Discov. 2018 Jun 28;4:72
pubmed: 30062053
Lung Cancer. 2012 May;76(2):197-203
pubmed: 22099218
Cell Death Dis. 2020 Feb 6;11(2):105
pubmed: 32029741
Protein Cell. 2018 Feb;9(2):196-206
pubmed: 28523433
J Mol Med (Berl). 2009 Jan;87(1):85-97
pubmed: 18974965
Nat Commun. 2018 Jan 22;9(1):322
pubmed: 29358673
Chem Phys Lipids. 2016 May;197:45-59
pubmed: 26200918
Mol Cell Biochem. 2018 Oct;447(1-2):217-224
pubmed: 29396722
Surg Endosc. 2017 Mar;31(3):1361-1370
pubmed: 27501728
Cancer Chemother Pharmacol. 2013 Jan;71(1):13-20
pubmed: 23073611
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncogenesis. 2016 Jan 25;5:e189
pubmed: 26807644
Anticancer Res. 2020 Sep;40(9):4843-4856
pubmed: 32878772
Biochem Biophys Res Commun. 2018 Oct 12;504(4):892-898
pubmed: 30224060
J Clin Med. 2020 Apr 12;9(4):
pubmed: 32290558
Dis Model Mech. 2013 Nov;6(6):1353-63
pubmed: 24203995
PLoS One. 2020 Jan 30;15(1):e0228010
pubmed: 31999740
Trends Mol Med. 2006 Jan;12(1):34-43
pubmed: 16325472
Nutrients. 2020 Jan 29;12(2):
pubmed: 32013225
Cancer Treat Rev. 2017 Jan;52:48-57
pubmed: 27889637
Lipids. 1987 Sep;22(9):627-36
pubmed: 3669925
FEBS Lett. 2007 Sep 18;581(23):4411-6
pubmed: 17719584
Cancer Res. 2008 Mar 15;68(6):1732-40
pubmed: 18339853
Biomed Res Int. 2018 Aug 15;2018:6437371
pubmed: 30186863
BMC Genomics. 2012 Jul 23;13:334
pubmed: 22823888
Cell Metab. 2020 Jan 7;31(1):62-76
pubmed: 31813823
Front Oncol. 2021 May 27;11:689701
pubmed: 34123858
Sci Rep. 2014 Aug 05;4:5959
pubmed: 25091112
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 15;858(1-2):287-91
pubmed: 17766199
Ann Surg. 2014 Jun;259(6):1138-49
pubmed: 23860197
Prostaglandins Leukot Essent Fatty Acids. 2017 May;120:25-31
pubmed: 28515019
Cancers (Basel). 2021 Jan 15;13(2):
pubmed: 33467532
Lipids Health Dis. 2007 Apr 05;6:10
pubmed: 17408498
Mol Oncol. 2014 Feb;8(1):39-49
pubmed: 24112879
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Mar;1865(3):158579
pubmed: 31794862
Oncotarget. 2015 Aug 7;6(22):18891-904
pubmed: 25970773
Sci Rep. 2021 Mar 17;11(1):6163
pubmed: 33731797
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Cells. 2020 Dec 04;9(12):
pubmed: 33291682
Adv Biol Regul. 2017 Jan;63:22-31
pubmed: 27697466
Cell Chem Biol. 2021 Jan 21;:
pubmed: 33571455
Oncol Rep. 2018 Dec;40(6):3489-3500
pubmed: 30272337